Peter Marks Purchases 1,818,182 Shares of Alterity Therapeutics Limited (ASX:ATH) Stock

Alterity Therapeutics Limited (ASX:ATH) insider Peter Marks acquired 1,818,182 shares of Alterity Therapeutics stock in a transaction on Monday, April 7th. The shares were bought at an average cost of A$0.01 ($0.01) per share, with a total value of A$20,000.00 ($12,345.68).

Alterity Therapeutics Price Performance

The firm has a market cap of $54.91 million, a PE ratio of -3.30 and a beta of 0.68.

About Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease.